These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

681 related items for PubMed ID: 21524390

  • 1. Regulatory considerations for developing drugs for rare diseases: orphan designations and early phase clinical trials.
    Pariser AR, Xu K, Milto J, Coté TR.
    Discov Med; 2011 Apr; 11(59):367-75. PubMed ID: 21524390
    [Abstract] [Full Text] [Related]

  • 2. Developing treatments for inborn errors: incentives available to the clinician.
    Haffner ME.
    Mol Genet Metab; 2004 Apr; 81 Suppl 1():S63-6. PubMed ID: 15050976
    [Abstract] [Full Text] [Related]

  • 3. The US Orphan Drug Act: rare disease research stimulator or commercial opportunity?
    Wellman-Labadie O, Zhou Y.
    Health Policy; 2010 May; 95(2-3):216-28. PubMed ID: 20036435
    [Abstract] [Full Text] [Related]

  • 4. FDA's proposed regulations to expand access to investigational drugs for treatment use: the status quo in the guise of reform.
    Rossen BR.
    Food Drug Law J; 2009 May; 64(1):183-223. PubMed ID: 19998746
    [Abstract] [Full Text] [Related]

  • 5. What the Orphan Drug Act has done lately for children with rare diseases: a 10-year analysis.
    Thorat C, Xu K, Freeman SN, Bonnel RA, Joseph F, Phillips MI, Imoisili MA.
    Pediatrics; 2012 Mar; 129(3):516-21. PubMed ID: 22371464
    [Abstract] [Full Text] [Related]

  • 6. Raising orphans: how clinical development programs of drugs for rare and common diseases are different.
    Orfali M, Feldman L, Bhattacharjee V, Harkins P, Kadam S, Lo C, Ravi M, Shringarpure DT, Mardekian J, Cassino C, Coté T.
    Clin Pharmacol Ther; 2012 Aug; 92(2):262-4. PubMed ID: 22739137
    [Abstract] [Full Text] [Related]

  • 7. Drugs for rare diseases: mixed assessment in Europe.
    Prescrire Int; 2007 Feb; 16(87):36-42. PubMed ID: 17323539
    [Abstract] [Full Text] [Related]

  • 8. Incentivizing Orphan Product Development: United States Food and Drug Administration Orphan Incentive Programs.
    Le TT.
    Adv Exp Med Biol; 2017 Feb; 1031():183-196. PubMed ID: 29214572
    [Abstract] [Full Text] [Related]

  • 9. The impact of the Orphan Drug Act on the development and advancement of neurological products for rare diseases: a descriptive review.
    Burke KA, Freeman SN, Imoisili MA, Coté TR.
    Clin Pharmacol Ther; 2010 Oct; 88(4):449-53. PubMed ID: 20856241
    [Abstract] [Full Text] [Related]

  • 10. Characteristics of orphan drug applications that fail to achieve marketing approval in the USA.
    Heemstra HE, Leufkens HG, Rodgers RP, Xu K, Voordouw BC, Braun MM.
    Drug Discov Today; 2011 Jan; 16(1-2):73-80. PubMed ID: 21094692
    [Abstract] [Full Text] [Related]

  • 11. Ethical imperatives of timely access to orphan drugs: is possible to reconcile economic incentives and patients' health needs?
    Rodriguez-Monguio R, Spargo T, Seoane-Vazquez E.
    Orphanet J Rare Dis; 2017 Jan 05; 12(1):1. PubMed ID: 28057032
    [Abstract] [Full Text] [Related]

  • 12. Quantitative analysis to guide orphan drug development.
    Lesko LJ.
    Clin Pharmacol Ther; 2012 Aug 05; 92(2):258-61. PubMed ID: 22739138
    [Abstract] [Full Text] [Related]

  • 13. Rare diseases, orphan drugs, and orphaned patients.
    Scheindlin S.
    Mol Interv; 2006 Aug 05; 6(4):186-91. PubMed ID: 16960139
    [No Abstract] [Full Text] [Related]

  • 14. Thirty Years of Orphan Drug Legislation and the Development of Drugs to Treat Rare Seizure Conditions: A Cross Sectional Analysis.
    Döring JH, Lampert A, Hoffmann GF, Ries M.
    PLoS One; 2016 Aug 05; 11(8):e0161660. PubMed ID: 27557111
    [Abstract] [Full Text] [Related]

  • 15. Navigating through orphan medicinal product regulations in EU and US--similarities and differences.
    Tiwari J.
    Regul Toxicol Pharmacol; 2015 Feb 05; 71(1):63-7. PubMed ID: 25497996
    [Abstract] [Full Text] [Related]

  • 16. Ethical considerations in orphan drug approval and use.
    Kesselheim AS.
    Clin Pharmacol Ther; 2012 Aug 05; 92(2):153-5. PubMed ID: 22814660
    [Abstract] [Full Text] [Related]

  • 17. Orphan drugs and orphan tests in the USA.
    Thoene JG.
    Community Genet; 2004 Aug 05; 7(4):169-72. PubMed ID: 15692190
    [No Abstract] [Full Text] [Related]

  • 18. Adopting orphan drugs--two dozen years of treating rare diseases.
    Haffner ME.
    N Engl J Med; 2006 Feb 02; 354(5):445-7. PubMed ID: 16452556
    [No Abstract] [Full Text] [Related]

  • 19. Orphan drug development: an economically viable strategy for biopharma R&D.
    Meekings KN, Williams CS, Arrowsmith JE.
    Drug Discov Today; 2012 Jul 02; 17(13-14):660-4. PubMed ID: 22366309
    [Abstract] [Full Text] [Related]

  • 20. [Orphan drugs: availability, reliability and reimbursement].
    Kreeftmeijer-Vegter AR, van Veldhuizen CK, de Vries PJ.
    Ned Tijdschr Geneeskd; 2012 Jul 02; 156(17):A4252. PubMed ID: 22531041
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 35.